AU2003207455B2 - S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer - Google Patents

S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer Download PDF

Info

Publication number
AU2003207455B2
AU2003207455B2 AU2003207455A AU2003207455A AU2003207455B2 AU 2003207455 B2 AU2003207455 B2 AU 2003207455B2 AU 2003207455 A AU2003207455 A AU 2003207455A AU 2003207455 A AU2003207455 A AU 2003207455A AU 2003207455 B2 AU2003207455 B2 AU 2003207455B2
Authority
AU
Australia
Prior art keywords
compound
significant
mer1
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003207455A
Other languages
English (en)
Other versions
AU2003207455A1 (en
AU2003207455A2 (en
Inventor
Hatice Dukale
Emil L Freireich
Hagop Kantarjian
Merida Sotelo-Lerma
Srdan Verstovsek
Ralph A Zingaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
The University of Texas System
Original Assignee
Texas A&M University System
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System, The University of Texas System, The University of Texas at Austin filed Critical Texas A&M University System
Publication of AU2003207455A1 publication Critical patent/AU2003207455A1/en
Publication of AU2003207455A2 publication Critical patent/AU2003207455A2/en
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE TEXAS A&M UNIVERSITY SYSTEM reassignment BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Amend patent request/document other than specification (104) Assignors: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, TEXAS A & M UNIVERSITY SYSTEM
Application granted granted Critical
Publication of AU2003207455B2 publication Critical patent/AU2003207455B2/en
Priority to AU2007249110A priority Critical patent/AU2007249110C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/66—Arsenic compounds
    • C07F9/70—Organo-arsenic compounds
    • C07F9/72—Aliphatic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003207455A 2002-01-07 2003-01-07 S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer Ceased AU2003207455B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007249110A AU2007249110C1 (en) 2002-01-07 2007-12-19 S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatment for cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34649202P 2002-01-07 2002-01-07
US60/346,492 2002-01-07
PCT/US2003/000281 WO2003057012A2 (en) 2002-01-07 2003-01-07 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007249110A Division AU2007249110C1 (en) 2002-01-07 2007-12-19 S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatment for cancer

Publications (3)

Publication Number Publication Date
AU2003207455A1 AU2003207455A1 (en) 2003-07-24
AU2003207455A2 AU2003207455A2 (en) 2003-07-24
AU2003207455B2 true AU2003207455B2 (en) 2007-09-20

Family

ID=23359639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003207455A Ceased AU2003207455B2 (en) 2002-01-07 2003-01-07 S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer

Country Status (6)

Country Link
US (4) US6911471B2 (enExample)
EP (3) EP1474128B1 (enExample)
JP (4) JP4571408B2 (enExample)
AU (1) AU2003207455B2 (enExample)
CA (1) CA2472633C (enExample)
WO (1) WO2003057012A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4571408B2 (ja) * 2002-01-07 2010-10-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン
TWI411431B (zh) * 2004-07-16 2013-10-11 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
AU2011204901B2 (en) * 2004-07-16 2013-09-12 Board Of Regents, The University Of Texas System Compounds and methods for treatment of cancer
ES2532666T3 (es) 2005-07-29 2015-03-30 Solasia Pharma K.K. Compuestos y métodos para el tratamiento del cáncer
CN101395166B (zh) * 2006-01-13 2014-07-09 得克萨斯州A&M大学系统 用于治疗癌症的化合物和方法
TW200829261A (en) 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
WO2008052279A1 (en) * 2006-11-01 2008-05-08 Newsouth Innovations Pty Limited Organo-arsenoxide compounds and use thereof
CN101903029B (zh) * 2007-11-02 2012-09-26 Zio医药肿瘤学公司 使用有机砷化物的联合治疗
BRPI0821002A2 (pt) * 2007-12-12 2015-06-16 Ziopharm Oncology Inc Compostos e métodos para o tratamento de câncer
BRPI0912175A2 (pt) * 2008-05-28 2015-10-06 Basf Se métodos para diagnosticar indução de enzima do fígado, para determinar se um composto é capaz de induzir indução de enzima do fígado em um indivíduo, e para identificar uma substância para tratar indução de enzima do fígado
CA2734650A1 (en) 2008-08-20 2010-02-25 Ziopharm Oncology, Inc. Organoarsenic compounds and methods for the treatment of cancer
JP5469779B2 (ja) * 2010-04-19 2014-04-16 エスアールアイ インターナショナル 多発性骨髄腫の治療のための組成物および方法
TWI617305B (zh) * 2013-12-05 2018-03-11 蘇愛康制藥有限公司 治療癌症的化合物及其應用程序
CN112941027B (zh) * 2021-03-19 2021-11-02 苏州大学 二甲基亚胂酸致人角质形成细胞恶性转化细胞株及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2349729A (en) * 1940-08-24 1944-05-23 Parke Davis & Co Therapeutic arsenic preparation
US2701812A (en) * 1951-06-26 1955-02-08 Dainippon Pharmaceutical Co Diarylarsenious acid derivatives and the preparation thereof
DE3229565A1 (de) * 1982-08-07 1984-02-16 Etschenberg, Eugen, Dr., 5000 Köln Arsenhaltige nucleoside
FR2640269B1 (fr) * 1988-12-13 1991-03-15 Maes Ludo Composes organometalliques, leurs modes de preparation et compositions pharmaceutiques les contenant
EP1391206B1 (en) 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
EP1002537A1 (en) 1998-10-30 2000-05-24 Assistance Publique, Hopitaux De Paris Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
KR20030014208A (ko) 2000-04-26 2003-02-15 오레곤 헬스 사이언시즈 유니버시티 티올계 화학보호제 화합물의 투여
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
AUPR598901A0 (en) 2001-06-28 2001-07-19 Unisearch Limited Inhibition of angiogenesis by targeting protein tyrosine phosphatases
EP1411876B1 (en) 2001-07-06 2009-10-28 Cochlear Limited Configuration of implanted devices
JP4571408B2 (ja) * 2002-01-07 2010-10-27 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン
JP4426456B2 (ja) 2002-11-07 2010-03-03 ニューサウス イノベイションズ ピーティーワイ リミテッド ミトコンドリア膜透過性遷移の誘導
TWI411431B (zh) 2004-07-16 2013-10-11 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
WO2008052279A1 (en) 2006-11-01 2008-05-08 Newsouth Innovations Pty Limited Organo-arsenoxide compounds and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
W.R. Cullen et al, Journal of Inorganic Biochemistry, 1984 21 (3) pp179 - 197 *

Also Published As

Publication number Publication date
JP2013237701A (ja) 2013-11-28
EP2462932A1 (en) 2012-06-13
JP4571408B2 (ja) 2010-10-27
WO2003057012A3 (en) 2004-07-08
JP2015120745A (ja) 2015-07-02
US7619000B2 (en) 2009-11-17
JP2005527487A (ja) 2005-09-15
JP5603593B2 (ja) 2014-10-08
EP1474128B1 (en) 2016-06-01
EP2420229A1 (en) 2012-02-22
US6911471B2 (en) 2005-06-28
JP2010090149A (ja) 2010-04-22
EP1474128A2 (en) 2004-11-10
WO2003057012A8 (en) 2004-04-01
CA2472633A1 (en) 2003-07-17
EP1474128A4 (en) 2006-05-03
AU2003207455A1 (en) 2003-07-24
US6995188B2 (en) 2006-02-07
US20080090904A1 (en) 2008-04-17
AU2003207455A2 (en) 2003-07-24
US20060189687A1 (en) 2006-08-24
US20050131062A1 (en) 2005-06-16
CA2472633C (en) 2014-07-08
WO2003057012A2 (en) 2003-07-17
US20040034095A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
US20080090904A1 (en) S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer
US20080090793A1 (en) Compounds and methods for the treatment of cancer
US20120022229A1 (en) Compounds and methods for the treatment of cancer
AU2007249110B2 (en) S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatment for cancer
HK1171952A (en) S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
HK1166959A (en) S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
Zingaro et al. S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer
AU2011204901B2 (en) Compounds and methods for treatment of cancer
Lerma et al. S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-APPLICANT FROM TEXAS A & M UNIVERSITY SYSTEM TO THE TEXAS A&M UNIVERSITY SYSTEM.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 FEB 2005

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired